KD01 / Wuhan Kaidejino Biotech - LARVOL DELTA

Bevacizumab-Primed Vascular Normalization Enhances Intratumoral Delivery and Efficacy of the tBID-Armed Oncolytic Adenovirus KD01 in Glioma. (PubMed, Front Biosci (Landmark Ed)) - "KD01 exerts potent tBID-mediated mitochondrial oncolytic activity against glioma cells. When used as a priming strategy, transient vascular normalization induced by bevacizumab enhanced the intratumoral efficacy of KD01 in an orthotopic glioma model while maintaining a favorable safety profile. These findings support a simple, sequence-dependent combination approach integrating anti-VEGF therapy with oncolytic virotherapy for the treatment of malignant gliomas."

Journal • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor • BID • CD31 • PECAM1

The Safety, Tolerability, and Efficacy of KD01 in Cervical Malignancies (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Tongji Hospital

New P1 trial • Oncolytic virus • Cervical Cancer • Oncology • Solid Tumor